Liver ischemia-reperfusion injury (IRI) represents a major risk factor of early graft dysfunction and a key obstacle to expanding the donor pool in orthotopic liver transplantation (OLT). Although graft autophagy is essential for resistance against hepatic IRI, its significance in clinical OLT remains unknown. Despite recent data identifying heme oxygenase-1 (HO-1) as a putative autophagy inducer, its role in OLT and interactions with sirtuin-1 (SIRT1), a key autophagy regulator, have not been studied. We aimed to 
hepatic tumor resection, and liver transplantation. Indeed, hepatic IRI has been recognized as a major risk factor for delayed early graft function and acute and chronic rejection as well as a key obstacle to expanding the donor organ pool. However, despite obvious clinical importance, mechanisms that account for liver IRI are only partially understood and no effective therapy is available to prevent or treat this condition in humans. 1 Autophagy is an evolutionarily conserved intracellular selfdigesting pathway responsible for maintaining energy homeostasis and removing long-lived or damaged organelles and proteins.
2 A growing body of evidence indicates a tissue-protective function for autophagy in various pathologic states, such as aging, diabetes, and neurodegenerative diseases, 3 as well as in liver IRI. [4] [5] [6] Although enhanced autophagy may represent a novel therapeutic target against IR damage, its efficacy and mechanism in OLT settings remain to be assessed, while clinical relevance of autophagy pathway in liver transplant patients has not been studied before.
Heme oxygenase-1 (HO-1; Hmox1), a rate-limiting enzyme that catalyzes the conversion of heme into biliverdin, carbon monoxide, and free iron, exerts potent antioxidative, anti-inflammatory, and cytoprotective functions. 7 We and others have reported on the beneficial function of HO-1 in hepatic IRI murine models by using chemical HO-1 inducers, [8] [9] [10] [11] adenovirus (Ad) gene transfer, 8, 12 and genetically modified animals. 13 Because macrophages are key mediators of innate immune-driven inflammation and the primary source of HO-1 in ischemia-reperfusion (IR)-stressed liver, 10, 14 we have established a novel molecular transfer approach by using ex vivo genetically modified HO-1-overexpressing macrophages. This regimen effectively transferred the target molecule into 40-50%
of hepatic cells and successfully alleviated warm IRI in mice 15, 16 ;
its putative efficacy in clinically relevant OLT models has not been tested. Although anti-inflammatory phenotype is central to HO-1 function in liver IRI, 17 recent studies have identified HO-1 as a novel hepatic autophagy inducer 18, 19 ; its role in liver transplantation remains unknown, and putative regulatory mechanisms need to be studied.
Sirtuin 1 (SIRT1), an NAD
+ -dependent type III histone/protein deacetylase involved in cellular senescence, inflammation, and stress resistance, 20 plays a key role in autophagy induction. 21, 22 In addition to an anti-inflammatory role in the pathogenesis of liver IRI, 23 recent studies have demonstrated the significance of SIRT1-induced autophagy in hepatocyte resistance against IR stress. 24,25 Molecular communication between SIRT1 and HO-1 in OLT has not been studied, and the mechanism by which SIRT1 may regulate the HO-1 autophagy pathway remains to be elucidated.
To gain further insight into HO-1-mediated autophagy in liver transplantation, we used an ex vivo genetically modified HO-1 macrophage adoptive transfer approach in a clinically relevant murine OLT model and analyzed human OLT samples (N = 51) in parallel.
Our translational study confirms the clinical relevance of HO-1 hepatoprotection and identifies SIRT1-dependent autophagy as a novel and essential regulator of HO-1 function in OLT under IR stress. 
| MATERIALS AND METHODS

| Clinical liver transplant study
| Animals
C57BL/6 mice aged 6-8 weeks were used (Jackson Laboratory, Bar
Harbor, ME). Animals were housed in the UCLA animal facility under specific pathogen-free conditions and received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" (National Institutes of Health publication 86-23 revised 1985). All studies were reviewed and approved by the UCLA Animal Research Committee.
| Generation of genetically modified bone marrow-derived macrophages
L929 cells (ATCC, Rockville, MD) were cultured in RPMI-1640 medium supplemented with 2 mmol/L l-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% fetal calf serum. The conditioned medium was collected from cells grown for 7 days. The bone marrowderived macrophages (BMMs) were generated according to standard procedures. 15 In brief, bone marrow cells were removed from the femurs and tibias of C57BL/6 mice and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mmol/L l-glutamine, with the addition of 15% L929-conditioned medium. Cells were cultured at 5 × 10 6 cells/well for 7 days with 5% CO 2 -95% air at 37°C and used for in vitro transfection.
Replication-defective recombinant Ad encoding HO-1 (AdHO-1) was generated as described. 15, 16 Liver and serum samples were collected 6 hours after reperfusion, the peak of hepatocellular damage in this model.
The sham group underwent the same procedures except for OLT.
| Serum biochemistry
sALT levels, an indicator of hepatocellular injury, were measured at IDEXX Laboratories (Westbrook, ME).
| Liver histology and IRI grading
Formalin-fixed paraffin-embedded OLT sections (5 μm) were stained with hematoxylin and eosin (HE). The severity of hepatic IRI was graded by using the Suzuki's criteria. . 32 The primer sequences are listed (Table S1 ). The expression of the target gene was normalized to the housekeeping gene HPRT. were used. To compare target protein expression in multiple human OLT samples, densitometry quantification was conducted by using a reference sample and normalization with β-actin as reported. 23 
| Western blot assay
| Immunohistochemistry
OLT-infiltrating neutrophils were detected by using monoclonal rat anti-Ly6G Abs (BD Biosciences, San Jose, CA). Immunostaining signals were visualized with a labeled polymer in the EnVision+ Kit (HPR;
Dako, Carpinteria, CA). Positively stained cells were counted blindly (10 HPF/section). LC3B expression in OLT was detected by using rabbit anti-LC3B Abs, and signals were visualized with secondary Abs:
Alexa Fluor 488 anti-rabbit IgG.
| TdT-mediated dUTP nick end labeling (TUNEL) assay
Cell death in formalin-fixed paraffin-embedded liver sections (5 μm)
was detected by use of the ApopTag Plus Peroxidase In Situ Apoptosis
Kit (Millipore, Temecula, CA). Results were scored semiquantitatively by blindly counting the number of positive cells in 10 HPF/section.
| Statistical analysis
In experiments in mice, group comparisons were performed by using a Student t-test. For human data, continuous values were analyzed by using a Mann-Whitney U test, and categorical variables were analyzed by using the Fisher exact test. The Spearman correlation coefficient (r) was used to evaluate the strength of linear relationship between variables. The cumulative survival rate was analyzed by using the KaplanMeier method, and differences between groups were compared by using a log-rank test. JMP for Windows 8.0 (SAS Institute, Cary, NC) was used for statistical analyses. A P-value of <.05 was considered statistically significant.
| RESULTS
| AdHO-1-transfected BMMs alleviate IRI in OLT
We +Adβ-gal BMMs = 3.3 ± 0.6; n = 4-6/group, P < .05, Figure 1C ) and preserved liver function, evidenced by sALT levels (OLT: + AdHO-1 BMMs = 3900 ± 2642 vs. OLT: + BMMs = 7997 ± 2068 or OLT:
+Adβ-gal BMMs = 7726 ± 2129 IU/L; mean ± SD, n = 4-6/group, P < .05, Figure 1C ) in AdHO-1 BMM-treated OLT. Thus, infusion of AdHO-1 BMMs into the graft enhanced HO-1 expression and minimized the adverse effects of hepatic IRI in OLT.
| AdHO-1 gene transfer promotes antiinflammatory signature in OLT
Because anti-inflammatory function is one of the key HO-1 biological features, 17 we examined whether AdHO-1 gene transfer alters the anti- 
| HO-1 expression correlates with IR liver damage and SIRT1/LC3B signaling in human OLT
Having demonstrated AdHO-1 BMM-facilitated hepatoprotection accompanied by increased SIRT1/LC3B levels in a murine OLT model, we next aimed to validate the relevance of these findings in human liver transplantation. Liver postreperfusion Bx specimens from 51 human OLTs were screened by Western blots for HO-1, SIRT1, and LC3B expression ( Figure 5A ). Hepatic HO-1 expression profile exhibited weak negative correlation with sALT levels at POD1 (r = -0.3306, P = .0178, Figure 5B ), indicating higher levels of HO-1 were associated with milder IR-liver injury. In addition, graft HO-1 expression showed positive correlation with SIRT1 (r = 0.4229, P = .0020, Figure 5C ) and weak positive correlation with LC3B (r = 0.3594, P = .0096, Figure 5D ).
To evaluate the impact of hepatic HO-1 on clinical outcomes, 51
OLT samples were split evenly into low (n = 26) and high (n = 25) HO-1 expression groups ( Figure 6A ). The patients' demographic data and clinical parameters are shown (Table S2 ). There was no correlation be- Figure 6E ). The high-HO-1 expression group was characterized by lower frequency of early graft dysfunction (3.8% vs 8.0%) and post-OLT rejection episodes (3.8% vs 16.0%). However, these differences failed to reach statistical significance (P = .5150 and P = .1871, respectively). Representative TUNEL and LC3B staining in low-versus high-HO-1 Bx groups are shown ( Figure 6F ).
| SIRT1 inhibition abrogates hepatoprotection and depresses autophagy despite HO-1 induction in mouse OLT
Based on the aforementioned preclinical and clinical data, preservation of hepatocellular function (sALT) and enhanced autophagy (LC3B)
in HO-1-overexpressing OLT was accompanied by increased SIRT1 signaling, a putative regulator of autophagy and stress resistance against hepatic IR damage. 25 Hence, we hypothesized SIRT1 might be essential in cytoprotection after HO-1 induction in IR-stressed OLT.
As shown in Figure 7A 
| DISCUSSION
This study is the first to document HO-1-mediated autophagy enhancement in human liver transplant settings and in a clinically relevant mouse OLT model. Although anti-inflammatory signaling is It is well documented that hepatocyte autophagy is essential in liver stress resistance. 4, 35, 36 Indeed, the loss of Atg4B increased sensitivity of aged mouse livers to warm IRI, 5 whereas rapamycin increased autophagy and protected against IR stress. 6 In contrast, recent studies in myeloid-specific Atg5 knockout mice have shed new light on macrophage autophagy regulation. [37] [38] [39] While macrophage Atg5 deficiency was shown to limit acute toxic liver injury by downregulating IL-1β, 38 the impaired macrophage Atg5 promoted proinflammatory macrophage polarization in obese mice. 37 Although macrophages are pivotal in innate immune-driven IR damage, the significance of macrophage autophagy in liver IRI, using myeloid autophagy-deficient animals, awaits future research.
Despite numerous preclinical reports identifying HO-1 as a major cytoprotective molecule, 10, 15, 16 Geuken and coworkers reported high "pre-transplant" HO-1 expression in human donor livers paradoxically correlated with augmented posttransplantation injury. 40 As Although aging and obesity are poor prognostic factors influencing HO-1 expression, we found no correlation between posttransplantation HO-1 levels and donor-recipient demographic parameters or surgical factors (Table S2 ). Because HO-1 is not only a cytoprotective molecule but also stress-inducible heat shock protein 32 (hsp32), its expression increases with the severity of IR stress. Paradoxically, high HO-1 levels were associated with more attenuated liver damage in the clinical arm of our study ( Figure 6D ). We speculate that the divergent HO-1 expression in OLT might be caused by varying individual inductivity of HO-1 in response to IR stress, resulting in varying susceptibility against IRI. Indeed, short guanine-thymine nucleotide repeats polymorphism in the promotor region on chromosome 22q13.1 of human HO-1 was shown to enhance HO-1 expression in response to oxidative stress, 42 whereas a more recent study associated HO-1 polymorphism with post-OLT hepatocellular damage. 43 As others failed to correlate HO-1 polymorphism with its expression profile, 40 more studies on putative factors influencing human HO-1 responses are warranted.
We have also recently reported on the anti-inflammatory and hepatoprotective role of SIRT1 activation in a warm liver IRI mouse model alongside negative correlation between SIRT1 and T-bet/IL-1β levels in 21 clinical OLT cases. 23 The positive SIRT1 regulation by HO-1 seen in a mouse IRI model was then confirmed in a 21-OLT patient cohort. 41 The current study documents the functional significance of the HO-1-SIRT1 axis in a clinically relevant mouse hepatic cold ischemia/OLT model ( Figure 4A ,B) and in 51 human OLT cases ( Figures 5C and 6B). Although in our previous clinical study (n = 21), post-OLT "high" HO-1 expression was accompanied by a statistically significant improvement in OLT survival, 41 we failed to detect a similar statistically significant survival difference in the current (n = 51) liver transplant patient cohort ( Figure 6E , P = .1963). As discussed earlier, 41 the link between graft and recipient long-term outcomes and IRI severity remains controversial. The presence of early lesions on the time-zero Bx in older grafts (n = 16) did not translate into early graft dysfunction or graft loss, 44 while histologic IRI grading in postreperfusion liver Bxs and peak transaminase levels (n = 55) did not show any correlation with clinical outcomes in the first posttransplantation month. 45 Likewise, despite preferable trends, our present study (n = 51) failed to detect significant differences in EAD, post-OLT rejection, or overall survival. In marked contrast, severe IRI on the time-zero Bx and peak of posttransplantation ALT in 476 OLT cases were significantly associated with a 1-year graft survival in an earlier study. 46 The correlation between graft/recipient outcomes and IRI severity may thus require considerably larger number of study subjects. Ad is an efficient vector for in vivo gene therapy due to its ability to mediate transgene expression in various cell types. However, serious off-target effects, including activation of innate immune responses, thrombocytopenia, coagulopathy, and liver damage, restrict systemic use of Ad vector in clinical practice. 50 In our present and previous preclinical studies, 15, 16 we used replication-defective recombinant Ad to generate HO-1-overexpressing BMMs. Indeed, the ex vivo genemodified local BMM infusion upregulated hepatic HO-1/LC3B expression and alleviated IRI in a mouse OLT model. This regimen makes Ad-related adverse effects negligible, 51 while direct BMM infusion into the liver improves macrophage transfer efficacy as a cellular delivery system for HO-1 trafficking into the disease site. 52 The present study using ex vivo gene-modified HO-1-overexpressing BMM in a clinically relevant mouse model is likely to validate and support future experiments in translational and clinical settings.
In our current study, the injection of BMMs (Adβ-gal) to OLT increased hepatic HO-1 expression compared with untreated BMM (no virus)-treated graft ( Figure 1A ). This result is consistent with our previous findings in a mouse model of liver warm IRI. 16 As a foreign pathogen, virus infection itself can cause cellular stress to activate antioxidant system, accompanied by increased antioxidant gene expression, such as manganese superoxide dismutase, HO-1, indoleamine-2,3-dioxygenase, and glutathione peroxidase. 53 We speculate that increased HO-1 expression following Adβ-gal BMM injection was induced by virus-related BMM stress, which was accompanied by increased SIRT1 and slightly higher LC3B levels ( Figure 4A ). However, 
